文献速递神经肿瘤

无框架立体定向活检在当代神经肿瘤学中的作用:活检胶质瘤患者的分子特征与诊断率

The role of frameless stereotactic biopsy in contemporary neuro-oncology: molecular specifications and diagnostic yield in biopsied glioma patients.
PubMed 文献 · J Neurooncol · 2018-11-02

该病例系列分析回顾了2011年1月至2017年10月共180例采用Brainlab® Varioguide系统的无框架立体定向活检,识别出119例胶质瘤患者。按2016中枢神经系统WHO标准重新处理样本后,92.4%的病例获得了包括分级和分子特征在内的完整诊断,IDH状态分析可行率为95.8%,累积突变率为9.6%。作者认为无框架立体定向活检在当代神经肿瘤学中似乎仍是有用的诊断工具,但应考虑某些潜在局限性。

要点

  • 119例胶质瘤患者中,92.4%的病例按2016中枢神经系统WHO标准获得了包括分级和分子特征在内的完整诊断。
  • IDH状态分析可行率为95.8%,累积突变率为9.6%。
  • 最常见的诊断为IDH野生型胶质母细胞瘤(66.4%),其次为IDH野生型间变性星形细胞瘤(21.8%)。

核心结论

  • 按2016中枢神经系统WHO标准,大多数病例获得了形式上完整的诊断,活检队列显示出预后不利的诊断和分子特征分布。
  • 无框架立体定向活检似乎被确认为当代神经肿瘤学中有用的诊断工具,但应考虑某些潜在局限性。

研究设计与样本

  • 病例系列分析,回顾了2011年1月至2017年10月共180例采用Brainlab® Varioguide系统的连续无框架立体定向活检,识别出疑似或确诊胶质瘤患者。
  • 神经病理样本按2016中枢神经系统WHO标准重新处理。

主要发现

  • 共识别出119例胶质瘤患者。
  • IDH状态分析可在95.8%的病例中进行,累积突变率为9.6%。
  • 110例(92.4%)获得了按2016中枢神经系统WHO标准包括分级和分子特征在内的完整诊断。
  • 4例的疾病实体被修订。
  • 最常见的诊断为IDH野生型胶质母细胞瘤(66.4%),其次为IDH野生型间变性星形细胞瘤(21.8%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: With the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 CNS WHO), diagnosis of glioma is based on molecular parameters in addition to histology potentially leading to additional demands on quality of tissue samples. This may challenge the role of minimally invasive biopsy procedures. This study aims to evaluate the diagnostic yield of glioma samples from frameless stereotactic biopsies with focus on molecular information and explore the neuromolecular profile of a glioma biopsy cohort. METHODS: In a case series analysis, 180 consecutive frameless stereotactic biopsies with the Brainlab® Varioguide system from January 2011 to October 2017 were reviewed and patients with suspected or verified glioma were identified. Neuropathological samples were reprocessed in accordance with 2016 CNS WHO standards. RESULTS: One hundred nineteen glioma patients were identified. Analysis of IDH status could be performed in 95.8% resulting in a cumulative mutation rate of 9.6%. A complete diagnosis according to 2016 CNS WHO including grading and molecular features was achieved in 110 cases (92.4%). Entities were revised in four cases. Most common diagnosis was IDH-wildtype glioblastoma (66.4%) followed by IDH-wildtype anaplastic astrocytoma (21.8%). CONCLUSIONS: A formally complete diagnosis according to 2016 CNS WHO was achieved in the majority of cases. The biopsy cohort showed a prognostically unfavorable distribution of diagnoses and molecular features. Frameless stereotactic biopsy seems to be confirmed as a useful diagnostic tool in contemporary neuro-oncology-however, certain potential limitations should be considered.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Mader MM, Rotermund R, Martens T, et al. The role of frameless stereotactic biopsy in contemporary neuro-oncology: molecular specifications and diagnostic yield in biopsied glioma patients. J Neurooncol. 2018. PMID: 30390175. doi:10.1007/s11060-018-03024-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。